Douglas G. 1993. Testimony before the Senate Labor and Human Resources Committee and the House Subcommittee on Health and the Environment. April 21. Washington, D.C.


Freeman P, Johnson K, Babcock J. 1993. A health challenge for the states: Achieving full benefit of childhood immunization. Occasional paper. February. The John W. McCormack Institute of Public Affairs, University of Massachusetts at Boston.


Garenne M, Leroy O, Beau J, Sene I. 1991. Child mortality after high-titre measles vaccines: Prospective study in Senegal. Lancet 338:903–907.


Halsey NA, Boulos R, Mode F, Andre J, Bowman L, Yaeger RG, Toureau S, Rhode I, Boulos C. 1983. Response to measles vaccine in Haitian infants 6–12 months old: influence of maternal antibodies, malnutrition and concurrent illnesses. New England Journal of Medicine 313:544–9.

Hlady GW, Bennett JV, Samadi AR, Begum J, Hafez A, Tarafdar AI, Boring JR. 1992. Neonatal tetanus in rural Bangladesh: Risk factors and toxoid efficacy. American Journal of Public Health 82:1365–1369.

Homma A. 1992. Technology Transfer. Paper presented to the WHO/CVI Task Force on Priority Setting and Strategic Plans. Children's Vaccine Initiative, World Health Organization, Geneva.

Homma A, Knouss RF. 1992. Transfer of vaccine technology to developing countries: The Latin American experience. Paper presented to the NIAID Conference on Vaccines and Public Health: Assessing Technologies and Policies for the Children's Vaccine Initiative, November 5–6. Bethesda, Maryland.


Institute of Medicine. 1986a. New Vaccine Development, Establishing Priorities. Volume I. Diseases of Importance in the United States. Washington, D.C.: National Academy Press.

Institute of Medicine. 1986b. New Vaccine Development, Establishing Priorities. Volume. II. Diseases of Importance in the Developing World. Washington, D.C.: National Academy Press.

Institute of Medicine. 1986c. Proceedings of a Workshop on Vaccine Supply and Innovation. Report for the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce. U.S. Congress, House. August. Washington, D.C.

Institute of Medicine. 1992. Emerging Infections. Washington, D.C.: National Academy Press.


Johnson KA. 1991. A National immunization registry: A proposal. Paper presented at the National Immunization Conference. June. Washington, D.C.


Kessler DA. 1992a. Letter to Representatives J. Dingell and N. Lent, September 14. U.S. Food and Drug Administration, Rockville, Maryland.

Kessler DA. 1992b. Testimony before Senate Subcommittee on Labor, Health and Human Services Committee on Appropriations. Childhood vaccine research and development issues. April. Washington, D.C.

Koop CE. 1993. In the dark about shots. February 10. Washington Post, p. A21.


Lancet. 1992. Noticeboard. Vaccines quality control deficient. Lancet 340:1282.


Marks P. 1993. Vaccines available but many children go without. February 14. The New York Times, Metro Section, p. 1.


National Institute of Allergy and Infectious Diseases. 1992a. The Jordan Report. Bethesda, Maryland.

National Institute of Allergy and Infectious Diseases. 1992b. Report of the Task Force on Microbiology and Infectious Disease. April. Bethesda, Maryland.

North American Vaccine. 1991. Annual Report. Beltsville, Maryland.


Patriarca P, Wright PF, John TJ. 1991. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review . Reviews in Infectious Diseases 13:926–939.


Siber G. 1992. Hib-DTP vaccine. Paper presented to the CVI Task Force on Priority Setting and Strategic Plans. Children's Vaccine Initiative, Geneva.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement